# A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations

> **NCT07746141** · PHASE1 · RECRUITING · sponsor: **BeOne Medicines** · enrollment: 100 (estimated)

## Conditions studied

- RAS Mutation
- Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** BG-85738
- **DRUG:** Tislelizumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT07746141
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-02
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746141, "A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*